Patent US4229478A successfully refreshed from Google Patents.
US4229478A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Naphthaquinone anti-psoriatic agents
Assignee: Syntex USA LLC
•
Filing: 1978-06-05
•
Granted: 1980-10-21
•
Expires: 1998-06-05
Abstract
Abstract Psoriasis in mammals is relieved by topically administering substituted naphthaquinones of the formula: <IMAGE> (I) where R1 and R2 are the same or different and are hydrogen, hydroxy, alkoxy or acylamino and R3 is hydrogen, halo, cyano or alkoxy with the proviso that R1 and R2 are not both hydrogen.
Inventors
- 👤 Gordon H. Jones
- 👤 John Young
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 14:19
CPC Classifications
C; C07; C07C; C07C50/00; C07C50/26; C07C50/32; A; A61; A61P; A61P17/00; C07C17/00; C07C17/093; C07C17/10; C07C17/14; C07C45/00; C07C45/51; C07C45/54; C07C46/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
103 words
A method for relieving the condition of psoriasis which comprises topically administering to mammals in need thereof an amount of a compound of the formula ##STR10## where R 1 and R 2 are the same or different and are hydrogen, hydroxy or C 1 to C 18 linear or branched alkoxy and R 3 is hydrogen, halo, cyano or C 1 to C 18 linear or branched alkoxy, with the proviso that R 1 and R 2 are not both hydrogen, sufficient to relieve the condition of psoriasis in mammals in combination with a pharmaceutically acceptable, non-toxic carrier suitable for said administration form.
Claim 2
Independent Claim
103 words
A method for relieving the condition of psoriasis which comprises topically administering to mammals in need thereof an amount of a compound of the formula ##STR10## where R 1 and R 2 are the same or different and are hydrogen, hydroxy or C 1 to C 18 linear or branched alkoxy and R 3 is hydrogen, halo, cyano or C 1 to C 18 linear or branched alkoxy, with the proviso that R 1 and R 2 are not both hydrogen, sufficient to relieve the condition of psoriasis in mammals in combination with a pharmaceutically acceptable, non-toxic carrier suitable for said administration form.
Claim 3
Dependent Claim
11 words
The method according to claim 1 wherein said compound is ##STR11##
Claim 4
Dependent Claim
31 words
The method according to claim 2 wherein R 1 and R 2 are hydroxy and R 3 is selected from the group halo, cyano, and C 1 to C 4 alkoxy.
Claim 5
Dependent Claim
27 words
The method according to claim 2 wherein R 1 is C 1 to C 4 linear or branched alkoxy and R 2 and R 3 are hydrogen.
Claim 6
Dependent Claim
18 words
The method according to claim 3 where R 3 is selected from the group fluoro, chloro and bromo.
Claim 7
Dependent Claim
11 words
The method according to claim 3 wherein R 3 is cyano.
Claim 8
Dependent Claim
14 words
The method according to claim 2 wherein the compound of formula (I) is 2,3-dihydroxy-6-bromo-1,4-naphthoquinone.
Claim 9
Dependent Claim
10 words
The method of claim 1 wherein said compound is 6-chloro-2,3-dihydroxy-1,4-naphthoquinone.
References Cited (Backward Citations)
US3914264A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-10-21 | 1984-04-21 | 1984-10-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-10-21 | 1988-04-21 | 1988-10-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-10-21 | 1992-04-21 | 1992-10-21 | $7700.00 | Window Closed / Lapsed |